Is the targeted drug Sotorasib a domestic drug?

The targeted drug Sotorasib (Sotorasib) is currently not produced and marketed in China. Sotoracib is not currently on the market in the country, so it is not covered by medical insurance. Sotoraxib is an oral medication that belongs to a class of drugs known as KRAS G12C inhibitors. The KRAS gene plays an important role in regulating cell growth and signaling in human cells. However, the G12C mutation of the KRAS gene is closely related to the occurrence and development of various cancers, especially non-small cell lung cancer (NSCLC). Sotorracib is usually recommended to be taken orally once daily. Each tablet of sotorracib has a dose of 960 mg and can be taken with food.